Glucose-6-phosphate dehydrogenase deficiency and the use of primaquine: top-down and bottom-up estimation of professional costs / Deficiência de glicose-6-fosfato desidrogenase e uso de primaquina: estimativa de custos de profissionais por macrocusteio e microcusteio

ABSTRACT The aim of this study has been to study whether the top-down method, based on the average value identified in the Brazilian Hospitalization System (SIH/SUS), is a good estimator of the cost of health professionals per patient, using the bottom-up method for comparison. The study has been developed from the context of hospital care offered to the patient carrier of glucose-6-phosphate dehydrogenase (G6PD) deficiency with severe adverse effect because of the use of primaquine, in the Brazilian Amazon. The top-down method based on the spending with SIH/SUS professional services, as a proxy for this cost, corresponded to R$60.71, and the bottom-up, based on the salaries of the physician (R$30.43), nurse (R$16.33), and nursing technician (R$5.93), estimated a total cost of R$52.68. The difference was only R$8.03, which shows that the amounts paid by the Hospital Inpatient Authorization (AIH) are estimates close to those obtained by the bottom-up technique for the professionals directly involved in the care.

RESUMO A pesquisa teve por objetivo estudar se o macrocusteio, baseado no valor médio identificado no Sistema de Internação Hospitalar (SIH/SUS), constitui um bom estimador do custo de profissionais de saúde por paciente, tendo como comparação o método de microcusteio. O estudo foi desenvolvido no contexto da assistência hospitalar oferecida ao portador da deficiência de glicose-6-fosfato desidrogenase (dG6PD) do sexo masculino com evento adverso grave devido ao uso da primaquina, na Amazônia Brasileira. O macrocusteio baseado no gasto em serviços profissionais do SIH/SUS, como proxy desse custo, correspondeu a R$60,71, e o microcusteio, baseado nos salários do médico (R$30,43), do enfermeiro (R$16,33) e do técnico de enfermagem (R$5,93), estimou um custo total de R$52,68. A diferença foi de apenas R$8,03, mostrando que os valores pagos pela Autorização de Internação Hospitalar (AIH) são estimadores próximos daqueles obtidos por técnica de microcusteio para os profissionais envolvidos diretamente no cuidado.

Analysis of the direct and indirect costs of treatment of imported malaria in the Slovak Republic / Análise dos custos diretos e indiretos do tratamento da malária importada na República Eslovaca

This study analyzed the approximate cost of treatment of patients hospitalized with a diagnosis of imported malaria in Slovakia. Between 2003 and 2007, 15 patients with imported malaria were hospitalized. The mean direct cost of the treatment was 970.75 euros and the mean indirect cost was 53.15 euros. For the patient with the highest cost of treatment, the use of mefloquine prophylaxis would have represented only 0.5 percent of the total direct cost of treating the disease. Despite the partial resistance of plasmodia, malaria chemoprophylaxis is unequivocally a cheaper choice than subsequent treatment of malaria.

Análise do custo aproximado do tratamento dos doentes hospitalizados na Eslováquia com malária importada. Entre 2003 a 2007, foram internados 15 doentes com malária importada. Os custos médios diretos do tratamento foram avaliados em 920,75 euros e indireto em 53,15 euros. No doente com o custo mais elevado de tratamento, a utilização da profilaxia com mefloquina representaria somente 0,5 por cento do total dos custos diretos do tratamento da doença. Apesar da resistência parcial do plasmódio, a quimioprofilaxia da malária é inequivocamente uma opção mais econômica do que o tratamento posterior da malária.

Costo efectividad del cambio de los esquemas de tratamiento para malaria en el Perú (1999-2003) / Cost-effectiviness of change in malaria treatment regimens in Peru (1999-2003)

Objetivos: Como respuesta a la emergencia de la resistencia del P. falciparum a los antimaláricos, el Ministerio de Salud del Perú decidió adoptar los esquemas de tratamiento para malaria combinados recomendados por la OMS: MQ-AS y SPAS, pero el costo de la nueva terapia es significativamente superior a los anteriores esquemas; SP y quinina + tetraciclina,sin embargo tendría como ventaja una mayor eficacia y probablemente la capacidad de disminuir la transmisión. Por estos motivos se evaluó de manera prospectiva el costo efectividad del cambio en los esquemas de tratamiento para malaria. Materiales y métodos: Se uso el método de análisis de decisiones y de riesgos, se construyó un modelo probabilístico que estableció las relaciones formales entre diversos factores que van a modificar el número de casos, muertes, los añosde vida ajustados por discapacidad (AVAD) y los costos del programa en un periodo de cinco años. Resultados: Se halló que si bien el costo unitario por tratamiento es mayor con el esquema de tratamiento combinado, el uso del nuevo esquema es más costo efectivo en reducir los AVADs. Conclusiones: En el marco de la estrategia del control de la malaria en el Perú, la terapia combinada es más costo efectiva que los anteriores esquemas.

Objectives: As a response to the emergency of P. falciparum resistence to antimalarial agents, Peruvian Ministry of Health decided to adopt combined treatment regimens for malaria recommended by World Health Organization: MQ, -AS and SP-AS, but the costs of the new therapy are significantly higher compared to former treatment regimens; SP and quinine + tetracyclin; however its advantage may be greater efficacy and probably its capacity for reducing transmission. For these reasons, we prospectively assessed costeffectiveness of changing treatment regimens for malaria. Materials and methods: Decision and risk analysis methods were used, a probabilistic model was build establishing formal relationships between different factors that may modify case number, death toll, disability-adjusted life years (DALYs), and program costs for a 5-year period. Results: Even though unit costs for drugs are higher with combined therapy, new combined therapy schedule has better cost-effectiveness for reducing life years adjusted for discapacity. Conclusions: Within the strategy for malaria control in Peru, combined therapy has better cost-effectiveness compared to former treatment regimens.

A cost-effectiveness analysis of three antimalarial treatments for acute, uncomplicated Plasmodium falciparum malaria in Mumbai, India.

BACKGROUND: Malaria is a major public health problem representing 2.3% of the overall global disease burden. The cost of treatment of malaria continues to rise as older drugs and insecticides become less effective and are replaced by more effective, but also more expensive products. METHODS: A post-hoc pharmacoeconomic analysis (direct and indirect costs only) of three antimalarials, chloroquine, mefloquine and co-artemether, was carried out to address the problem of switch to a more expensive first-line antimalarial in the face of growing chloroquine resistance. RESULTS: From the perspective of a large public hospital, it was seen that in an area of high grade chloroquine resistance, the total expenditure on patients who fail chloroquine would exceed the excess expenditure on mefloquine when the RII + RIII resistance exceeded 9%. CONCLUSIONS: Switch to a more expensive drug like mefloquine as a first-line option would be cost-effective when the moderate-severe chloroquine resistance exceeded 9%.

Acceptance of short course artesunate plus mefloquine drug combination by malaria patients in rural Myanmar.

A cross sectional study was carried out in a rural area of Myanmar to identify malaria patients' acceptance of artesunate plus mefloquine drug combination and to determine the cost borne by patients. The majority (88.5%) preferred this new regimen rather than the other ones they had used before; conviction of drug efficacy was the reason given for the preference by most of them. Traveling on foot to rural health centers or a health assistant's residence for getting the drugs was found to be the main route. Average cost incurred by a patient to get the drug was found to be 274.22 Kyats. Among the cost items, drug cost was the highest item that they had used.

Malaria in Cambodia.

There are around half a million cases of malaria with 5-10,000 deaths per year in Cambodia. Incidence rates vary in different parts of the country. Malaria control is hampered by multiple drug resistance of Plasmodium falciparum, inaccessibility to the major vector, poor security in most malarious areas, and lack of resources. The control strategy emphasises improvement of clinical management and provision of prompt and accurate diagnosis in order to reduce morbidity and to prevent mortality. In addition health information and drug distribution systems are being improved. The use of pyrethroid-treated mosquito nets and health education are being promoted. Particular attention is given to returning refugees as they settle into the country.